|
Collaborative arrangements (Textuals 1) (Details) (USD $)
In Millions, unless otherwise specified |
3 Months Ended | 12 Months Ended | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
Sep. 30, 2012
|
Jun. 30, 2012
|
Mar. 31, 2012
|
Dec. 31, 2011
|
Sep. 30, 2011
|
Jun. 30, 2011
|
Mar. 31, 2011
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2010
|
||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||||
| Product sales | $ 4,337 | $ 4,201 | $ 4,200 | $ 3,901 | $ 3,907 | $ 3,877 | [1] | $ 3,893 | $ 3,618 | $ 16,639 | $ 15,295 | $ 14,660 | ||
|
Collaborative Arrangement With Glaxo Group Limited [Member] | Primary Territories [Member]
|
||||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||||
| Product sales | 139 | 62 | 5 | |||||||||||
|
Collaborative Arrangement With Glaxo Group Limited [Member] | Selling General and Administrative [Member]
|
||||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||||
| Cost recoveries | 10 | 30 | 46 | |||||||||||
|
Collaborative Arrangement With Glaxo Group Limited [Member] | Other Revenues [Member]
|
||||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||||
| Milestone payments received | $ 75 | |||||||||||||
|
||||||||||||||